Leadership
Executive Leadership Team
Invicro was founded by a small group who recognized a need for a fully integrated portfolio of imaging solutions and a shared goal of being a research partner for anyone needing medical imaging services or software solutions. Since founding the company, Invicro’s leadership team has grown the business organically with a focus on providing innovation and solutions for drug discovery and development.
Headshots by David Shopper Photography
Edward J Hogan Jr, M.S.
Chief Operating Officer
Edward J Hogan Jr, M.S.
Chief Operating Officer
Ed Hogan has over thirty years of experience in clinical research, managing and executing early Phase I through Phase 4 imaging trials in both the Pharmaceutical and CRO space. He has more than twenty years of experience in managing clinical operations, including extensive experience leading cross-functional teams, including Operations (Project, Image and Data Management), Engineering (Development and Validation) and Medical and Scientific Services. Ed has progressive business experience in building and managing global cross-functional teams supporting clinical trials focusing teams on delivery, accountability, and customer satisfaction while driving quality and process improvements. As COO, Ed oversees Invicro’s primary Business Units (Clinical Services, Discovery and Preclinical Services) as well as Clinic and Lab Services, Corporate Operations, Commercial Sales, and Quality and Regulatory.
Ciara Finucane, MSc
VP, Discovery & Preclinical Services
Ciara Finucane, MSc
VP, Discovery & Preclinical Services
Ms. Ciara Finucane joined Invicro in January 2013 and specializes in nuclear techniques, including the evaluation of molecular targets for radionuclide-mediated diagnosis and therapy of cancer. With over 15 years of experience, Ms. Finucane specializes in preclinical SPECT and PET imaging with a focus on the design, execution and project management of nuclear imaging studies.
Ms. Finucane received her honors degree in Physiology from Trinity College Dublin and her MSc in Forensic Sciences from Kings College London. Prior to Invicro, Ms. Finucane developed cancer therapeutic and imaging agents for the Center for Molecular Imaging at Bart’s Cancer Institute at Queen Mary University of London.
Denise Ferraiolo, BA
SVP, Clinical Operations
Denise Ferraiolo, BA
SVP, Clinical Operations
Ms. Denise Ferraiolo has twenty plus years of experience in clinical research, managing and executing early Phase I through Phase 4 trials. More specifically, Denise has more than ten years of leadership experience, with an emphasis on operational expertise. Ms. Ferraiolo has a strong background in operations and the conductance of imaging trials, with a concentration on managing global cross-functional teams in Project and Data Management, Imaging Services and Clinic Operations. Her focus is on delivery, accountability, and customer satisfaction while driving quality and process improvements.
At Invicro, Ms. Ferraiolo oversees the oversees the Clinical Services group responsible for Project Management, Imaging Services, Data Management, Reader Management and Clinic/Chemistry functions for early and late phase clinical trials.
Benjamin Murphy, CPA
VP, Finance
Benjamin Murphy, CPA
VP, Finance
Mr. Ben Murphy joined Invicro in 2017 and has previously served as Invicro’s Financial Controller.
Mr. Murphy has over 10 years of experience specializing in Pharma, Biotech and CRO businesses under public and private reporting environments. At Invicro, Mr. Murphy leads the Accounting and Finance functions including treasury, financial controls, budgeting and financial reporting. He is a Certified Public Accountant in the state of Massachusetts and an active member of the AICPA. Mr. Murphy received his B.S. Degree in Accounting from the University of Connecticut School of Business.
Jan Passchier, PhD
EVP, Global Head of Laboratories & Clinics
Jan Passchier, PhD
EVP, Global Head of Laboratories & Clinics
Dr. Jan Passchier is a radiochemistry expert who specializes in imaging and drug development. He holds a PhD in PET radiochemistry from Groningen University. Dr. Passchier started his career at GlaxoSmithKline where he identified and developed novel tool compounds for a large variety of CNS, metabolic and respiratory indications.
Dr. Passchier played a significant role in the design and realization of the GlaxoSmithKline Clinical Imaging Centre where he headed the chemistry group. Following a spin-out of the center to Imanova Ltd, now part of Invicro, his role expanded to include operational responsibility for the business. Dr. Passchier has a keen interest and deep understanding of the application of molecular imaging to disease understanding and drug development.
Eugenii (Ilan) Rabiner, MD
EVP, Head of Translational Applications
Eugenii (Ilan) Rabiner, MD
EVP, Head of Translational Applications
Dr. Ilan Rabiner is a psychiatrist and psychopharmacologist who was part of the team that set up the GlaxoSmithKline Clinical Imaging Centre, which transitioned to become Imanova in Sep 2011. Dr. Rabiner spent 10 years at GlaxoSmithKline, and was head of Clinical Imaging Applications at the Translational Medicine and Technologies group.
Dr. Rabiner received a BSc in Physiology and Medical Biochemistry and a MBBCh, from the University of the Witwatersrand, and specialist training in psychiatry at the University of Cape Town. He was trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London.
Dr. Rabiner’s research interests focus on the application of molecular imaging to human pathophysiology, psychopharmacology and central nervous system drug development. He is an author of >140 peer reviewed publications.
Fiona Roberts
VP, Site Operations UK
Fiona Roberts
VP, Site Operations UK
Ms. Fiona Roberts has over 24 years of experience in the molecular imaging field, and provides site leadership and oversight of all operational activities at the Invicro facility in London.
She joined Invicro London (formerly Imanova) in 2015 as Clinical Operations Manager overseeing the delivery of imaging studies in support of clinical research. Prior to Invicro, Ms. Roberts held key commercial clinical operations roles at Alliance Medical and HCA International in London. Previously, she held instrumental roles at Austin Health in Melbourne, Australia and Guy’s and St Thomas NHS Trust London, where she gained her clinical SPECT and PET imaging experience.
Ms. Roberts holds a Bachelor of Applied Science in Medical Radiations from the Royal Melbourne Institute of Technology.
Piran Sucindran
VP, Global Head of Quality and Regulatory
Piran Sucindran
VP, Global Head of Quality and Regulatory
Mr. Piran Sucindran leads the global quality and regulatory organization at Invicro, with teams overseeing Quality Systems, Third Party QA Oversight, Chemistry QA, Systems Compliance, and Regulatory Affairs.
Mr. Sucindran has over 15 years’ experience working in clinical research, specializing in Good Clinical Practice and Good Manufacturing Practice. Mr. Sucindran has experience working both in the UK National Health Service and the commercial sector. He is a member of the Research Quality Association GCP Committee, has completed an MSc in Quality Management in Scientific Research and Development and BSc in Molecular Medicine.
Joeseph Vacca, MS
VP, Business Development
SCIENTIFIC ADVISORS
Phillip Kuo, MD, PhD
Distinguished Scientist
Phillip Kuo, MD, PhD
Distinguished Scientist
Dr. Kuo is board-certified in Internal Medicine and Radiology with a special certification in Nuclear Medicine and was Chief of Nuclear Medicine for a university medical center for 10 years. Dr. Kuo has more than 100 publications and has served as principal investigator and co-principal investigator on multiple NIH grants and investigator-initiated trials.
Dr. Kuo’s experience includes design and supervision of phase I-III clinical trials including theranostics with PET, SPECT, MRI, and radiotherapeutics. Dr. Kuo’s experience also includes participation in USFDA and EMA meetings for regulatory approval. As a reader for clinical trials, he has reviewed over ten thousand scans for oncology or neurology.
Kenneth Marek, MD
Distinguished Scientist
Kenneth Marek, MD
Distinguished Scientist
Ken is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS.
John Seibyl, MD
Distinguished Scientist
John Seibyl, MD
Distinguished Scientist
John is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. John is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Kenneth Marek, he has directed and continues to direct several international multicenter imaging studies. John is an author on over hundred publications on CNS imaging.